CO2019007023A2 - Antagonistas de integrinas - Google Patents
Antagonistas de integrinasInfo
- Publication number
- CO2019007023A2 CO2019007023A2 CONC2019/0007023A CO2019007023A CO2019007023A2 CO 2019007023 A2 CO2019007023 A2 CO 2019007023A2 CO 2019007023 A CO2019007023 A CO 2019007023A CO 2019007023 A2 CO2019007023 A2 CO 2019007023A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical agents
- compounds
- integrins
- integrin antagonists
- αvβ8
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 3
- 108010044426 integrins Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440253P | 2016-12-29 | 2016-12-29 | |
| US201762471882P | 2017-03-15 | 2017-03-15 | |
| PCT/US2017/068801 WO2018132268A1 (en) | 2016-12-29 | 2017-12-28 | Integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019007023A2 true CO2019007023A2 (es) | 2019-07-31 |
Family
ID=62840040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0007023A CO2019007023A2 (es) | 2016-12-29 | 2019-06-28 | Antagonistas de integrinas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11306084B2 (https=) |
| EP (1) | EP3562826A4 (https=) |
| JP (1) | JP2020504120A (https=) |
| KR (1) | KR20190100232A (https=) |
| CN (1) | CN110177787A (https=) |
| AU (1) | AU2017393297A1 (https=) |
| BR (1) | BR112019012515A2 (https=) |
| CA (1) | CA3045491A1 (https=) |
| CO (1) | CO2019007023A2 (https=) |
| IL (1) | IL267686A (https=) |
| MX (1) | MX2019007797A (https=) |
| PH (1) | PH12019501514A1 (https=) |
| RU (1) | RU2019116820A (https=) |
| WO (1) | WO2018132268A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110177787A (zh) | 2016-12-29 | 2019-08-27 | 圣路易斯大学 | 整合素拮抗剂 |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| FI3844162T3 (fi) | 2018-08-29 | 2025-03-27 | Morphic Therapeutic Inc | Alfa v beeta6 -integriinin estäjiä |
| EP4086254B1 (en) | 2018-08-29 | 2024-12-18 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| JP2026500719A (ja) * | 2022-12-27 | 2026-01-08 | プライアント・セラピューティクス・インコーポレイテッド | アルファ－ｖ－ベータ－８インテグリン阻害剤及びその使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004511434A (ja) * | 2000-06-15 | 2004-04-15 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
| EP1572690A1 (en) | 2002-12-20 | 2005-09-14 | Pharmacia Corporation | Thiazole compounds as integrin receptor antagonists derivatives |
| BR0317600A (pt) | 2002-12-20 | 2005-11-29 | Pharmacia Corp | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina |
| JP2006513218A (ja) * | 2002-12-20 | 2006-04-20 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニスト誘導体としてのピラゾール化合物 |
| US8716226B2 (en) * | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| WO2014015054A1 (en) * | 2012-07-18 | 2014-01-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| MX2019005234A (es) | 2016-11-08 | 2019-08-12 | Squibb Bristol Myers Co | Amidas y aminas de azol como inhibidores de integrina alfa v. |
| SI3538528T1 (sl) | 2016-11-08 | 2021-03-31 | Bristol-Myers Squibb Company | Pirol amidi kot alfa v integrin inhibitorji |
| AU2017359025A1 (en) | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors |
| KR102506327B1 (ko) | 2016-11-08 | 2023-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | αV 인테그린 길항제로서의 인다졸 유도체 |
| WO2018089353A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
| CN110177787A (zh) | 2016-12-29 | 2019-08-27 | 圣路易斯大学 | 整合素拮抗剂 |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020009889A1 (en) | 2018-07-03 | 2020-01-09 | Saint Louis University | ALPHAvBETA1 INTEGRIN ANTAGONISTS |
-
2017
- 2017-12-28 CN CN201780080614.7A patent/CN110177787A/zh active Pending
- 2017-12-28 BR BR112019012515-9A patent/BR112019012515A2/pt not_active Application Discontinuation
- 2017-12-28 CA CA3045491A patent/CA3045491A1/en not_active Abandoned
- 2017-12-28 RU RU2019116820A patent/RU2019116820A/ru not_active Application Discontinuation
- 2017-12-28 US US16/474,505 patent/US11306084B2/en active Active
- 2017-12-28 WO PCT/US2017/068801 patent/WO2018132268A1/en not_active Ceased
- 2017-12-28 KR KR1020197019720A patent/KR20190100232A/ko not_active Withdrawn
- 2017-12-28 AU AU2017393297A patent/AU2017393297A1/en not_active Abandoned
- 2017-12-28 MX MX2019007797A patent/MX2019007797A/es unknown
- 2017-12-28 JP JP2019534956A patent/JP2020504120A/ja active Pending
- 2017-12-28 EP EP17891632.6A patent/EP3562826A4/en not_active Withdrawn
-
2019
- 2019-06-26 IL IL267686A patent/IL267686A/en unknown
- 2019-06-27 PH PH12019501514A patent/PH12019501514A1/en unknown
- 2019-06-28 CO CONC2019/0007023A patent/CO2019007023A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL267686A (en) | 2019-08-29 |
| EP3562826A4 (en) | 2020-08-26 |
| US20190345155A1 (en) | 2019-11-14 |
| JP2020504120A (ja) | 2020-02-06 |
| EP3562826A1 (en) | 2019-11-06 |
| WO2018132268A1 (en) | 2018-07-19 |
| AU2017393297A1 (en) | 2019-06-13 |
| KR20190100232A (ko) | 2019-08-28 |
| RU2019116820A (ru) | 2021-01-29 |
| PH12019501514A1 (en) | 2020-09-14 |
| CN110177787A (zh) | 2019-08-27 |
| CA3045491A1 (en) | 2018-07-19 |
| US11306084B2 (en) | 2022-04-19 |
| MX2019007797A (es) | 2019-10-21 |
| WO2018132268A8 (en) | 2019-06-20 |
| BR112019012515A2 (pt) | 2019-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019007023A2 (es) | Antagonistas de integrinas | |
| MX2012015189A (es) | Producto detergente. | |
| ECSP18066504A (es) | Compuestos de piperidina sustituido y su uso | |
| MX380691B (es) | Derivados policiclicos activos como plaguicidas con sustituyentes que contienen azufre. | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| UY34797A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| UY34161A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen | |
| MX381933B (es) | Bolsitas que comprenden materiales de pared fibrosos solubles en agua y metodos para su fabricacion. | |
| MX2016001480A (es) | Formulacion de inhibidores de syk. | |
| PE20131493A1 (es) | Amidas aminoindanes con una alta actividad fungicida y sus composiciones fitosanitarias | |
| BR112015032336A2 (pt) | artigos para cuidados pessoais | |
| CR20190332A (es) | Inhibidores selectivos de jak1 | |
| MX2018009459A (es) | Derivado de sulfonamida y composicion farmaceutica que contiene el mismo. | |
| IL280827A (en) | Integrin alpha 4 antagonists and compositions comprising same for use in treating ocular conditions | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| EP3481814A4 (en) | TETRAHYDRONAPHTHYRIDINPENTANAMID integrin antagonists | |
| MX2016002483A (es) | Bolsitas que comprenden materiales de pared de pelicula perforados y metodos para su fabricacion. | |
| PE20151052A1 (es) | Trans-4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-n,n-dimetilcarbamoil-ciclohexilamina para el tratamiento de sintomas negativos de la esquizofrenia | |
| BR112015008389A2 (pt) | compostos úteis na síntese de compostos de benzamida | |
| EA201990158A1 (ru) | Производные бензодиоксана и их фармацевтическое применение | |
| MX384151B (es) | Variantes de desintegrina y usos farmacéuticos de las mismas. | |
| MX2015007424A (es) | Composiciones y/o articulos con solubilidad mejorada de un activo solido. | |
| BR112018013548A2 (pt) | lenço não tecido, embalagem | |
| AR113270A1 (es) | Compuesto de heteroarilo con contenido de nitrógeno y su uso farmacéutico |